These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 3699575)

  • 1. In vivo chemosensitivity testing in patients with gynecologic malignancies and nude mouse xenografts by monitoring cell kinetic parameters and DNA distribution patterns: a preliminary report.
    Sevin BU; Pollack A; Averette HE; Ramos R; Greening SE; Evans D
    Gynecol Oncol; 1986 May; 24(1):27-40. PubMed ID: 3699575
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vivo cell kinetic effects of cis-platinum on human ovarian cancer xenografts measured by dual parameter flow cytometry.
    Sevin BU; Pollack A; Averette HE; Ramos R; Donato D
    Cytometry; 1987 Mar; 8(2):153-62. PubMed ID: 3582063
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DNA flow cytometry of ovarian tumors with correlation to histopathology.
    Feichter GE; Kühn W; Czernobilsky B; Müller A; Heep J; Abel U; Haag D; Kaufmann M; Rummel HH; Kubli F
    Int J Gynecol Pathol; 1985; 4(4):336-45. PubMed ID: 3002995
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Heterogeneity of glutathione content in human ovarian cancer.
    Lee FY; Vessey A; Rofstad E; Siemann DW; Sutherland RM
    Cancer Res; 1989 Oct; 49(19):5244-8. PubMed ID: 2766292
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [An experimental study of cisplatin and it's antidote, sodium thiosulfate, in ovarian pseudomyxoma implanted into nude mice abdominal cavity].
    Miyahara K; Miyoshi T; Kobayashi H; Hamai J; Tomoo Y; Yamada T; Nishimura H; Yakushiji M; Kato T
    Nihon Sanka Fujinka Gakkai Zasshi; 1986 Jul; 38(7):1066-70. PubMed ID: 3746025
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vivo chemosensitivity test models for gynecologic malignancies. Methodology and results.
    Kleine W
    Contrib Gynecol Obstet; 1994; 19():76-81. PubMed ID: 7995055
    [No Abstract]   [Full Text] [Related]  

  • 7. Prognostic significance of S-phase fraction as measured by DNA flow cytometry in gynecologic malignancies.
    Strang P; Stendahl U; Tribukait B
    Ann N Y Acad Sci; 1993 Mar; 677():354-63. PubMed ID: 8494220
    [No Abstract]   [Full Text] [Related]  

  • 8. [-Chemosensitivity testing in gynecologic oncology. Experiences with an ATP bioluminescence assay-].
    Kurbacher CM; Mallmann P; Kurbacher JA; Hübner H; Krebs D
    Geburtshilfe Frauenheilkd; 1996 Feb; 56(2):70-8. PubMed ID: 8647362
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Flow cytometer (FCM) in biological characteristics of nasopharyngeal carcinoma xenografts in nude mice].
    Cao SL; Liu TF; Wang ZH; Huang KM; Zhou J; Li DL; Ni HZ; Sang JZ; Wang Y; Zhang BN
    Zhonghua Zhong Liu Za Zhi; 1987 Jan; 9(1):6-9. PubMed ID: 3595429
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Cancer chemo-endocrine therapy and its cell biological basis].
    Nishiya I
    Hum Cell; 1998 Sep; 11(3):109-14. PubMed ID: 10086273
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ovarian tumour xenografts in the study of the biology of human epithelial ovarian cancer.
    Friedlander ML; Russell P; Taylor IW; Tattersall MH
    Br J Cancer; 1985 Mar; 51(3):319-33. PubMed ID: 3882111
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chemotherapy in advanced ovarian cancer.
    Schein PS
    Geriatrics; 1973 Dec; 28(12):89-95. PubMed ID: 4128004
    [No Abstract]   [Full Text] [Related]  

  • 13. Clinical prediction of experimental chemotherapy of gynecological tumor xenografts.
    Kleine W
    Behring Inst Mitt; 1984 May; (74):337-42. PubMed ID: 6477361
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Resistance formation in the cytostatic treatment of carcinomas].
    Heckmann U; Tranckjer AS; Harms J
    Zentralbl Gynakol; 1969 Sep; 91(37):1204-10. PubMed ID: 5368211
    [No Abstract]   [Full Text] [Related]  

  • 15. [Relation between DNA content in ovarian cystadenoma and its pathohistology].
    Sun ZC
    Zhonghua Fu Chan Ke Za Zhi; 1993 Dec; 28(12):731-3, 760-1. PubMed ID: 8137645
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug resistance features and S-phase fraction as possible determinants for drug response in a panel of human ovarian cancer xenografts.
    Kolfschoten GM; Hulscher TM; Pinedo HM; Boven E
    Br J Cancer; 2000 Oct; 83(7):921-7. PubMed ID: 10970695
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Primary study of arsenic trioxide inhibits abdomino-metastatic tumor formation of human ovarian carcinoma in nude mice and its mechanisms].
    Huang SG; Kong BH; Yang RF; Jiang S
    Ai Zheng; 2002 Apr; 21(4):401-4. PubMed ID: 12452020
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quantitative nuclear DNA analysis of human ovarian adenocarcinoma: compared before and after chemotherapy and correlated with clinical response.
    Dobashi K; Stratton JA; Teplitz RL; Liao SY; Braly PS; Disaia PJ
    Gynecol Oncol; 1986 May; 24(1):81-90. PubMed ID: 3754529
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fine needle aspiration biopsy in gynecologic malignancies. Recurrent and metastatic lesions.
    Dey P; Dhar KK; Nijhawan R; Karmakar T; Khajuria A
    Acta Cytol; 1994; 38(5):698-701. PubMed ID: 8091900
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Destruction of human solid tumors by alkyl lysophospholipids.
    Runge MH; Andreesen R; Pfleiderer A; Munder PG
    J Natl Cancer Inst; 1980 Jun; 64(6):1301-6. PubMed ID: 6929370
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.